Rules-Based Medicine, Inc

Description

Rules-Based Medicine, Incorporated Awarded Funding from the Cancer Prevention and Research Institute of Texas Multimillion Dollar Award to Expand OncologyMAP™ Program for Novel Cancer Tests AUSTIN, TX (June 23, 2010) — Rules-Based Medicine, Incorporated (RBM) today announced the Cancer Prevention and Research Institute of Texas (CPRIT) has granted it a Company Commercialization Award to expand and enhance the OncologyMAP™ program for discovery and development of novel diagnostic and prognostic cancer tests. The award of approximately $3 million will fund research and development to more than double the number of cancer-associated biomarker assays in RBM's new OncologyMAP™ product. Read More Rules-Based Medicine and Psynova Neurotech Announce Companion Diagnostic Collaboration with Roche Utilizing Psynova's schizophrenia biomarker portfolio and RBM's DiscoveryMAP™ technology AUSTIN, TX (December 2, 2009) — Rules-Based Medicine, Incorporated (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia. Read More Rules-Based Medicine Forms Biomarker Alliance with Covance Incorporated Deal Expands Access to Clinical Trials Market for Multiplexed Biomarker Services SAN DIEGO, CA — November 18, 2009 — Rules-Based Medicine, Incorporated (RBM) today announced it has entered into a biomarker alliance and services agreement with Covance Incorporated (NYSE:CVD) that will provide biotechnology and pharmaceutical companies with a powerful combination of biomarker technologies and services for use in drug development. Under terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM shall use Covance as its exclusive referral source for laboratory testing services. Financial terms of the agreement were not disclosed. Read More Rules-Based Medicine, Incorporated Names Don Beamish to Lead Sales & Marketing for Diagnostic Expansion AUSTIN, Texas — November 11, 2009 — Rules-Based Medicine, Incorporated (RBM), today announced that Don Beamish has joined the Company as vice president, commercial development. In this newly created position Beamish will leverage his neuroscience pharmaceutical marketing expertise in leading sales and marketing initiatives to support the intended launch of RBM's neuropsychiatric diagnostics services. RBM recently announced the identification of a biomarker panel demonstrating clinical utility for the differential diagnosis of schizophrenia. Read More Rules-Based Medicine Introduces CardiovascularMAP™ Multiplex Biomarker Panel To Aid CVD Development Austin, Texas, October 28, 2009 — Rules-Based Medicine (RBM), a leading multiplexed biomarker testing laboratory, today announced the launch of CardiovascularMAP™, a research tool designed specifically to advance drug development aimed at the treatment of cardiovascular disease (CVD).

Fact sheet

Products & services

Similar companies nearby